Previous Article | Next Article ![]()
Journal of Virology, October 2004, p. 11070-11076, Vol. 78, No. 20
0022-538X/04/$08.00+0 DOI: 10.1128/JVI.78.20.11070-11076.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Gabriela Bleiber,2,
Priya Duggal,3 George Nelson,1 Margaret May,4 Bastien Mangeat,5 Irene Alobwede,6 Didier Trono,5 David Vlahov,7 Sharyne Donfield,8 James J. Goedert,9 John Phair,10 Susan Buchbinder,11 Stephen J. O'Brien,12 Amalio Telenti,2 and Cheryl A. Winkler1*
Basic Research Program, SAIC Frederick, National Cancer Institute-Frederick Cancer Research and Development Center,1 Laboratory of Genomic Diversity, National Cancer Institute, Frederick,12 Inherited Disease Research Branch, National Human Genome Research Institute,3 Johns Hopkins University Bloomberg School of Public Health, Baltimore,7 Viral Epidemiology Branch, National Cancer Institute, Bethesda, Maryland,9 Rho Inc., Chapel Hill, North Carolina,8 Fineberg School of Medicine, Northwestern University, Comprehensive AIDS Center, Chicago, Illinois,10 San Francisco Department of Public Health, San Francisco, California,11 Institute of Microbiology, University of Lausanne, Lausanne,2 Department of Genetics and Microbiology, University of Geneva,5 Division of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland,6 Department of Social Medicine, University of Bristol, Bristol, United Kingdom4
Received 18 February 2004/ Accepted 2 June 2004
The cytosine deaminase APOBEC3G, in the absence of the human immunodeficiency virus type 1 (HIV-1) accessory gene HIV-1 viral infectivity factor (vif), inhibits viral replication by introducing G
A hypermutation in the newly synthesized HIV-1 DNA negative strand. We tested the hypothesis that genetic variants of APOBEC3G may modify HIV-1 transmission and disease progression. Single nucleotide polymorphisms were identified in the promoter region (three), introns (two), and exons (two). Genotypes were determined for 3,073 study participants enrolled in six HIV-AIDS prospective cohorts. One codon-changing variant, H186R in exon 4, was polymorphic in African Americans (AA) (f = 37%) and rare in European Americans (f < 3%) or Europeans (f = 5%). For AA, the variant allele 186R was strongly associated with decline in CD4 T cells (CD4 slope on square root scale: 1.86, P = 0.009), The 186R allele was also associated with accelerated progression to AIDS-defining conditions in AA. The in vitro antiviral activity of the 186R enzyme was not inferior to that of the common H186 variant. These studies suggest that there may be a modifying role of variants of APOBEC3G on HIV-1 disease progression that warrants further investigation.
Supplemental material for this article may be found at http://jvi.asm.org/.
P.A. and G.B. contributed equally to this work.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|